VCNX Key Statistics, Chart & Performance
The current stock price of VCNX is 1.41 USD. In the past month the price decreased by -54.66%. In the past year, price decreased by -85.66%.
VCNX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to VCNX. When comparing the yearly performance of all stocks, VCNX is a bad performer in the overall market: 99.22% of all stocks are doing better.
VCNX Financial Highlights
Over the last trailing twelve months VCNX reported a non-GAAP Earnings per Share(EPS) of -12.16. The EPS increased by 85.54% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -382.72% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
VCNX Forecast & Estimates
VCNX Ownership
About VCNX
Company Profile
Vaccinex, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Rochester, New York and currently employs 37 full-time employees. The company went IPO on 2018-08-09. The firm is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including neurodegenerative diseases, cancer, and autoimmune disorders. Its lead product candidate, pepinemab, is in clinical development for the treatment of Alzheimer’s disease, head and neck, pancreatic and breast cancer. Its lead platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. SEMA4D antibody platform is the application of its knowledge of SEMA4D biology to develop pepinemab for the treatment of various diseases and conditions, including cancer. ActivMAb antibody discovery platform is a human antibody discovery platform based on a method for expressing multipass membrane proteins, as well as large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of mammalian pox viruses.
Company Info
VACCINEX INC
1895 Mount Hope Ave
Rochester NEW YORK 14620 US
CEO: Maurice Zauderer
Employees: 39
Phone: 15852712700
VACCINEX INC / VCNX FAQ
What does VACCINEX INC do?
Vaccinex, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Rochester, New York and currently employs 37 full-time employees. The company went IPO on 2018-08-09. The firm is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including neurodegenerative diseases, cancer, and autoimmune disorders. Its lead product candidate, pepinemab, is in clinical development for the treatment of Alzheimer’s disease, head and neck, pancreatic and breast cancer. Its lead platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. SEMA4D antibody platform is the application of its knowledge of SEMA4D biology to develop pepinemab for the treatment of various diseases and conditions, including cancer. ActivMAb antibody discovery platform is a human antibody discovery platform based on a method for expressing multipass membrane proteins, as well as large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of mammalian pox viruses.
Can you provide the latest stock price for VACCINEX INC?
The current stock price of VCNX is 1.41 USD. The price decreased by -61.37% in the last trading session.
Does VACCINEX INC pay dividends?
VCNX does not pay a dividend.
What is the ChartMill technical and fundamental rating of VCNX stock?
VCNX has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Is VACCINEX INC (VCNX) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on VCNX.
What is VACCINEX INC worth?
VACCINEX INC (VCNX) has a market capitalization of 3.78M USD. This makes VCNX a Nano Cap stock.